Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ladprao General Hospital Public Company Limited (LPH.BK)
Bangkok, TH
Ladprao General Hospital Public Company Limited, including its subsidiaries, functions as a prominent healthcare provider in Thailand, primarily through the operation of the private Ladprao General Hospital. This facility offers an extensive range of medical specialties, such as neurology, cardiology, hypertension management, dentistry, hemodialysis, pediatrics, refractive eye surgery, women's health, aesthetic and dermatological services, laser treatments, and ear, nose, and throat care. The hospital also hosts specialized centers for health screenings, gastroenterology, hepatology, orthopedics, physical therapy, and rehabilitation. Expanding beyond direct patient care, the company delivers scientific analytical and diagnostic services for industries including food, agriculture, pharmaceuticals, and environmental protection. It further conducts instrument calibration, quality inspections, and provides certifications that adhere to stringent quality systems and international benchmarks. Other ventures include hospital management and consulting, mobile health check-ups, and professional nursing services for industrial sites and other organizations. Moreover, the company actively researches, develops, cultivates, and distributes herbal products with medicinal benefits. Established in 1990, Ladprao General Hospital Public Company Limited is headquartered in Bangkok, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.54% | -0.54% | -2.13% | -2.65% | -0.54% | -1.08% | +2.79% | -29.23% | -28.54% | -57.21% | -26.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Care Facilities: +10.2%+7.8% Q1'26: -0.7% (vs Q1'25)
-
EPS growth Medical - Care Facilities: +19.2%+145.5% ★ Q1'26: +14.1% (vs Q1'25)
-
FCF margin FCF growth · Medical - Care Facilities: +32.0%+14.1% ★ Q1'26: +5.0% (vs Q1'25)
-
EBIT margin Medical - Care Facilities: +11.3%+9.2% Q1'26: +7.3% (vs Q1'25)
-
ROIC Medical - Care Facilities: +6.8%+9.6% ★ Q1'26: +7.5% (vs Q1'25)
-
Share dilution Medical - Care Facilities: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Care Facilities: 0.99×1.21× ★ Q1'26: 0.88× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.24B
est: 1.20B (+3.8%)
|
1.33B
est: 1.30B (+2.5%)
|
1.43B
est: 1.42B (+0.2%)
|
1.53B
est: 1.58B (-3.2%)
|
1.58B
est: 1.57B (+0.6%)
|
1.80B
est: 1.80B (+0.0%)
|
2.50B
est: 2.43B (+2.8%)
|
2.42B
est: 2.42B (0.0%)
|
2.23B
est: 2.12B (+5.1%)
|
2.40B
est: 2.36B (+1.5%)
|
2.59B
est: 2.59B (+0.0%)
|
| EBITDA |
202.92M
est: 230.64M (-12.0%)
|
233.20M
est: 249.30M (-6.5%)
|
305.44M
est: 274.15M (+11.4%)
|
292.42M
est: 303.28M (-3.6%)
|
234.21M
est: 302.51M (-22.6%)
|
307.39M
est: 346.58M (-11.3%)
|
732.71M
est: 468.20M (+56.5%)
|
539.02M
est: 465.12M (+15.9%)
|
297.85M
est: 408.74M (-27.1%)
|
341.02M
est: 457.52M (-25.5%)
|
455.37M
est: 500.32M (-9.0%)
|
| EBIT |
145.05M
est: 139.54M (+3.9%)
|
163.50M
est: 150.84M (+8.4%)
|
232.31M
est: 165.87M (+40.1%)
|
192.70M
est: 183.50M (+5.0%)
|
132.19M
est: 183.03M (-27.8%)
|
172.06M
est: 209.69M (-17.9%)
|
585.25M
est: 283.28M (+106.6%)
|
380.64M
est: 281.42M (+35.3%)
|
102.60M
est: 247.30M (-58.5%)
|
117.63M
est: 273.68M (-57.0%)
|
238.35M
est: 299.28M (-20.4%)
|
| Net Income |
100.45M
est: 86.40M (+16.3%)
|
155.90M
est: 152.35M (+2.3%)
|
193.83M
est: 176.40M (+9.9%)
|
156.95M
est: 159.98M (-1.9%)
|
110.49M
est: 125.99M (-12.3%)
|
142.89M
est: 133.20M (+7.3%)
|
464.52M
est: 378.00M (+22.9%)
|
322.91M
est: 324.00M (-0.3%)
|
63.55M
est: 187.20M (-66.1%)
|
78.18M
est: 144.00M (-45.7%)
|
196.60M
|
| SGA |
141.57M
est: 190.19M (-25.6%)
|
189.66M
est: 205.58M (-7.7%)
|
176.27M
est: 226.06M (-22.0%)
|
239.14M
est: 250.09M (-4.4%)
|
240.37M
est: 249.45M (-3.6%)
|
282.60M
est: 285.79M (-1.1%)
|
333.61M
est: 386.08M (-13.6%)
|
349.23M
est: 383.54M (-8.9%)
|
399.18M
est: 337.05M (+18.4%)
|
431.60M
est: 392.42M (+10.0%)
|
500.10M
est: 429.13M (+16.5%)
|
| EPS |
0.17
est: 0.12 (+41.7%)
|
0.21
est: 0.21 (-0.8%)
|
0.26
est: 0.25 (+6.1%)
|
0.21
est: 0.22 (-5.5%)
|
0.15
est: 0.17 (-14.3%)
|
0.20
est: 0.19 (+8.1%)
|
0.65
est: 0.53 (+23.8%)
|
0.45
est: 0.45 (+0.0%)
|
0.09
est: 0.26 (-66.0%)
|
0.11
est: 0.20 (-45.0%)
|
0.27
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 4/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ungoon Chantanavanich | Chief Executive Officer & Director | 268.0K | — |
| Chomsri Chaiwachirasak | Deputy Department Administrator of Finance & Accounting | — | female |
| Jirawan Meanghong | Managing Director | — | female |
| Sawanan Wacharavanich | Medical Department Administrator & QC Managing Director | — | — |
| Vitavas Pirmphol | Deputy Department Administrator & Company Secretary | — | male |
| Wittawat Permpon | Corporate Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LPH.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
